Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Open Access Gateway

Technetium-99m-Labelled Sulesomab (LeukoScan) in the Evaluation of Soft Tissue Infections

Quigley A.-M. · Gnanasegaran G. · Buscombe J.R. · Hilson A.J.W.

Author affiliations

Department of Nuclear Medicine, Royal Free Hospital, London, UK

Corresponding Author

Dr. J.R. Buscombe

Nuclear Medicine Department, Royal Free Hospital

Pond Street

London NW3 2QG (UK)

Tel. +44 20 7830 2470, Fax +44 20 7472 6202, E-Mail j.buscombe@medsch.ucl.ac.uk

Related Articles for ""

Med Princ Pract 2008;17:447–452

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


Objective: To perform a retrospective review of all patients receiving technetium-99m (99mTc)-labelled sulesomab over a 4-year period to determine if soft tissue infections can be accurately identified. Methods and Materials: We reviewed the results of 124 99mTc-sulesomab studies performed over a 4-year period. Of these, 34 were performed for undiagnosed fever in which soft tissue infection was suspected to be the main cause. The patients’ clinical notes, microbiology reports and other imaging findings were reviewed to determine the clinical outcome following the scan. The scans were regarded as being true-positives if (i) uptake correlated with the site from which fluid or tissue was obtained and which grew bacteria, and/or (ii) the site of abnormality was reported as having an infection on other imaging or (iii) there was a clinical correlation with the referring clinician’s evaluation of the patient. Planar imaging was performed using standard protocols, together with single-photon emission computed tomography (if required) at 1 and 4 h after injection of 20–30 mCi (740–1,110 MBq) 99mTc-sulesomab. Results: Three patients were unevaluable. In the remaining 31 patients, 21 99mTc-sulesomab studies were regarded as true-positives and 6 patients had true-negative scans. One patient had a false-positive scan (abnormal uptake with negative microbiology) and 3 had false-negative scans (infection confirmed but a negative scan). Conclusion: In suspected soft tissue infection, 99mTc-sulesomab imaging has a sensitivity of 88% with a specificity of 86% and overall accuracy of 87%. 99mTc-sulesomab provides an accurate method of imaging for suspected soft tissue infection, which is also fast and convenient, as cell labelling is not required.

© 2008 S. Karger AG, Basel


  1. Ryan PJ: Leukoscan for orthopaedic imaging in clinical practice. Nucl Med Commun 2002;23:707–714.
  2. Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, Chilvers ER, Peters AM: Mechanism of accumulation of 99mTc-sulesomab in inflammation. J Nucl Med 2003;44:11–18.
  3. Becker W: Bone and soft tissue; in Cox PH, Buscombe JR (eds): The Imaging of Infection and Inflammation. Amsterdam, Kluwer, 1998, pp 199–217.
  4. Hakki S, Harwood SJ, Morissey MA, Camblin JG, Laven DL, Webster WB: Comparative study of monoclonal antibody scan in diagnosing orthopaedic infection. Clin Orthop 1997;335:275–285.
  5. Annovazzi AA, Bagni BB, Burroni LC, D’Alessandria CA, Signore AA: Nuclear medicine imaging of inflammatory/infective disorders of the abdomen. Nucl Med Commun 2005;26:657–664.
  6. Love C, Tronco GG, Palestro CJ: Imaging of infection and inflammation with 99mTc-fanolesomab. Q J Nucl Med Mol Imaging 2006;50:113–120.
  7. Sciuk J, Brandau W, Vollet B, Stucker R, Erlemann R, Bartenstein P, Peters PE, Schober O: Comparison of technetium-99m polyclonal human immunoglobulin and technetium-99m monoclonal antibodies for imaging chronic osteomyelitis: first clinical results. Eur J Nucl Med 1991;18:401–407.
  8. Shanthly N, Aruva MR, Zhang K, Mathew B, Thakur ML: 99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. Q J Nucl Med Mol Imaging 2006;50:104–112.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: August 26, 2007
Accepted: November 13, 2007
Published online: October 03, 2008
Issue release date: October 2008

Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 1

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: https://www.karger.com/MPP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.